Gaza doctor's death in Israeli strike devastates medical community
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Health Line
an hour ago
- Health Line
8 Complementary and Natural Therapies for Hidradenitis Suppurativa
Key takeaways Hidradenitis Suppurativa (HS) is a skin condition that causes painful lumps under the skin. Complementary therapies, used together with prescribed treatments, may offer you some relief. Natural remedies, like turmeric and tea tree oil, might help reduce inflammation and pain. Always talk with your doctor before trying new treatments to make sure they are safe for you to take. Lifestyle changes, such as eating a healthy diet and reducing stress, can help improve your symptoms. Regular exercise and quitting smoking may also support better skin health. What is hidradenitis suppurativa? Hidradenitis suppurativa (HS) is a chronic (long-term) inflammatory condition that causes painful, fluid-filled lesions, often on areas of the body where skin touches skin. This occurs when bacteria gather in blocked hair follicles, resulting in inflammation. If you're living with HS, chances are you're currently taking some form of treatment for your condition. This may include medications like: biologics antibiotics hormone therapy However, HS symptoms can be unpredictable, and you've likely experienced periods when you could use some extra relief during a flare-up. The following natural therapies are generally safe to use in combination with other HS treatments and may help you manage breakout-related discomfort. Talk with a doctor before starting any of these therapies to make sure it's right for you. Tea tree oil Tea tree oil has antibacterial properties and may help reduce the number of skin lesions in acne. While HS also features lesions, it's not a form of acne, so tea tree oil may not have the same effect. Currently, there's not enough research to confirm the benefits of tea tree oil for either acne or HS. Be careful — tea tree oil is toxic if swallowed. It should only be used topically to treat HS. Some tea tree oils can be applied directly from the bottle, while some need to be diluted in a carrier oil (like sweet almond oil) before use. Follow the manufacturer's directions. If you haven't used tea tree oil before, make sure to first check for allergic reactions by placing a drop of the oil on your forearm for 12 to 24 hours. If you don't have a reaction like skin irritation, you can apply it to other areas. While research suggests there are health benefits, the FDA doesn't monitor or regulate the purity or quality of essential oils. It's important to talk with a healthcare professional before you begin using essential oils and be sure to research the quality of a brand's products. Always do a patch test before trying a new essential oil. Research suggests that the foods you eat may affect HS, but the best diet to manage the condition is unclear. Still, following an anti-inflammatory diet may make a difference in the frequency and severity of your breakouts. Some foods that may contribute to flare-ups include: sugar dairy nightshade vegetables, such as: eggplant peppers potatoes tomatoes Try to eliminate them in favor of anti-inflammatory options, like: oily fish nuts leafy greens Foods containing brewer's yeast (pizza dough, cake, beer) have also been found to possibly worsen HS symptoms. However, it's unknown whether brewer's yeast affects all people with HS or just those with a wheat intolerance. More studies need to be done on diet and hidradenitis suppurativa. Until there's more information, pay attention to foods that may be linked to HS symptoms and consider temporarily eliminating them from your diet to see if your symptoms improve. Turmeric Turmeric is a plant similar to ginger that contains antibacterial and anti-inflammatory qualities, much like tea tree oil. Unlike tea tree oil, however, turmeric is nontoxic and can be applied topically or ingested as a supplement to help prevent infection and reduce inflammation. Turmeric is commonly used as a complementary remedy for HS. It may help with symptoms by reducing inflammation. However, more research needs to be done to confirm its effectiveness. Compresses Applying a cold or warm compress directly to an HS lesion may temporarily relieve pain in the affected area. A 2020 study found that participants reported using warm compresses more than other forms of pain relief. However, they rated this therapy as less effective than using marijuana or opioids. You can make a warm compress using a washcloth and hot water. After wringing out the water, place the washcloth on the affected area for 10 minutes. Aloe vera Aloe vera is one of the most commonly known treatments for skin conditions and wound healing. Although there isn't evidence to suggest it will heal your lesions, its cooling properties may help soothe some of the pain associated with HS. Apply topical aloe vera lotion directly to the area of your breakout twice per day. Make sure to use pure aloe vera that's free from chemical additives, as some additives can cause irritation. As with tea tree oil, it's important to apply a small amount of aloe vera to your forearm to test for allergies before using it for the first time. Wait 12 to 24 hours to check for a reaction before using it on other parts of your body. Natural deodorant In general, it may be best to avoid using deodorant entirely if you have HS. If you choose to use deodorant, switching to a natural, aluminum-free deodorant might help you avoid irritation around lesions on your underarms. However, there isn't much research on the effects of deodorant on people with HS. Loose-fitting clothes Adjusting your wardrobe may relieve some of the discomfort caused by an HS flare-up and improve your quality of life. Avoid wearing tight fabrics. Instead, opt for looser, more breathable clothing. If your lesions are mostly around your breasts or upper thighs, try switching to bras without an underwire or underwear that's made without tight elastic or seams. Loose boxers may be less irritating than briefs. Bleach bath Adding a small amount of bleach to a warm bath may help treat bacterial infections and reduce inflammation. To take a bleach bath, DermNet NZ recommends you add 1/3 teaspoon of 2.2 percent household bleach for every 4 cups of bathwater. Soak for 10 to 15 minutes. Be careful to not put your head in the water or get any of the water in your mouth or eyes. After your bleach bath, rinse off in the shower and pat the sensitive areas dry with a soft towel. More research needs to be done on the effectiveness of using bleach baths for HS. Takeaway HS doesn't have a cure. Still, lifestyle changes and treatments may help improve your symptoms. It may take time to find treatments that are effective for you. It's important to note that there's a twofold higher rate of HS in people who smoke. If you're living with HS and you smoke, quitting may help your condition.
Yahoo
an hour ago
- Yahoo
Axogen Showcases Nerve Repair Vision at Goldman Sachs
Axogen, Inc. (NASDAQ:AXGN) is among the best growth stocks to invest in for the next 5 years. On June 11, 2025, Axogen, Inc. (NASDAQ:AXGN) presented at the Goldman Sachs 46th Annual Global Healthcare Conference, where a strategic vision was highlighted that is focused on solidifying the company's leadership in nerve repair solutions. The management remains confident about the giant's position in delivering strong growth while expanding the product portfolio. The company is undergoing a wave of transformative operational changes by adding new clinical application areas. With that being said, Axogen, Inc. (NASDAQ:AXGN) is working towards improving professional education activities and entering new areas. An orthopedic surgeon connecting peripheral nerves with AxoGuard Nerve Connector, showing the precision and care of AxoGuard's products. The future outlook of Axogen, Inc. (NASDAQ:AXGN) looks equally promising. The company aims to expand internationally by 2026, with sustained investments in Avance and complementary products, targeting regeneration and protection devices. It doesn't stop there; recognizing significant under-penetration in its existing markets, the company is committed to accelerating growth by advancing its commercial footprint and development initiatives. Axogen, Inc. (NASDAQ:AXGN) is a Florida-based company that develops and markets technologies for peripheral nerve regeneration and repair worldwide. The company's core offerings include Avance Nerve Graft, AxoGuard Nerve Connector, AxoGuard Nerve Protector, AxoGuard Nerve Cap, and AxoGuard HA+ Nerve Protector. Founded in 2002, the company is focused on improving patients' lives. While we acknowledge the potential of AXGN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Hemostemix Closes $469,366 Private Placement
Calgary, Alberta--(Newsfile Corp. - July 4, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") announces that the TSX Venture Exchange ("TSXV") conditionally approved the Company's previously disclosed non-brokered private placement (the "Offering") in the amount of CAD $469,366. The Offering consisted of the issuance of 3,911,385 Common Shares at a price of CAD $0.12. As per TSXV Policy 4.1, the investor is arm's length to the Company and is not a Related Party to the Company at the time of disclosure. The use of proceeds will be allocated to general working capital purposes, supporting the Company's continuing operational expenses and business development activities. The Company confirms that there is no material fact or material change about the Company that has not been generally disclosed. All securities issued in connection with the Offering are subject to a four-month hold period from the closing date under applicable Canadian securities laws, in addition to such other restrictions as may apply under applicable securities laws of jurisdictions outside Canada. ABOUT HEMOSTEMIXHemostemix is an autologous stem cell therapy platform company, founded in 2003. A winner of the World Economic Forum Technology Pioneer Award, the Company has developed, patented, is scaling and selling autologous (patient's own) blood-based stem cell therapy, VesCell (ACP-01). Hemostemix has completed seven clinical studies of 318 subjects and published its results in ten peer reviewed publications. ACP-01 is safe, clinically relevant and statistically significant as a treatment for peripheral arterial disease, chronic limb threatening ischemia, non ischemic dilated cardiomyopathy, ischemic cardiomyopathy, congestive heart failure, and angina. Hemostemix completed its Phase II clinical trial for chronic limb threatening ischemia and published its results in the Journal of Biomedical Research & Environmental Science. As compared to a five year mortality rate of 60% in the CLTI patient population, UBC and U of T reported to the 41st meeting of vascular surgeons: 0% mortality, cessation of pain, wound healing in 83% of patients followed for up to 4.5 years, as a midpoint result. For more information, please visit For further information, please contact: Thomas Smeenk, President, CEO & Co-Founder: EM: tsmeenk@ / PH: 905-580-4170 Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined under the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Forward-Looking Information: This news release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical fact, included herein are forward-looking information. In particular, this news release contains forward-looking information in relation to the Closing of a non brokered private placement, in furtherance of sales in Florida of VesCell (ACP-01), and the commercialization of ACP-01 via the sale of compassionate treatments under Florida SB 1768. There can be no assurance that such forward-looking information will prove to be accurate. Actual results and future events could differ materially from those anticipated in such forward-looking information. This forward-looking information reflects Hemostemix's current beliefs and is based on information currently available to Hemostemix and on assumptions Hemostemix believes are reasonable. These assumptions include, but are not limited to: the underlying value of Hemostemix and its Common Shares; the successful resolution of any litigation that Hemostemix is pursuing or defending (the "Litigation"); the results of ACP-01 research, trials, studies and analyses, including the analysis being equivalent to or better than previous research, trials or studies; the receipt of all required regulatory approvals for research, trials or studies; the level of activity, market acceptance and market trends in the healthcare sector; the economy generally; consumer interest in Hemostemix's services and products; competition and Hemostemix's competitive advantages; and, Hemostemix obtaining satisfactory financing to fund Hemostemix's operations including any research, trials or studies, and any Litigation. Forward-looking information is Subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Hemostemix to be materially different from those expressed or implied by such forward-looking information. Such risks and other factors may include, but are not limited to: the ability of Hemostemix to complete clinical trials, complete a satisfactory analyses and file the results of such analyses to gain regulatory approval of a phase II or phase III clinical trial of ACP-01; potential litigation Hemostemix may face; general business, economic, competitive, political and social uncertainties; general capital market conditions and market prices for securities; delay or failure to receive board or regulatory approvals; the actual results of future operations including the actual results of future research, trials or studies; competition; changes in legislation affecting Hemostemix; the timing and availability of external financing on acceptable terms; long-term capital requirements and future developments in Hemostemix's markets and the markets in which it expects to compete; lack of qualified, skilled labour or loss of key individuals; and risks related to the COVID-19 pandemic including various recommendations, orders and measures of governmental authorities to try to limit the pandemic, including travel restrictions, border closures, non-essential business closures service disruptions, quarantines, self-isolations, shelters-in-place and social distancing, disruptions to markets, disruptions to economic activity and financings, disruptions to supply chains and sales channels, and a deterioration of general economic conditions including a possible national or global recession or depression; the potential impact that the COVID-19 pandemic may have on Hemostemix which may include a decreased demand for the services that Hemostemix offers; and a deterioration of financial markets that could limit Hemostemix's ability to obtain external financing. A description of additional risk factors that may cause actual results to differ materially from forward-looking information can be found in Hemostemix's disclosure documents on the SEDAR website at Although Hemostemix has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. Readers are cautioned that the foregoing list of factors is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking information as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Forward-looking information contained in this news release is expressly qualified by this cautionary statement. The forward-looking information contained in this news release represents the expectations of Hemostemix as of the date of this news release and, accordingly, it is Subject to change after such date. However, Hemostemix expressly disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law. To view the source version of this press release, please visit Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
